Chancery OKs $2.3M Deal To End Cancer Drug Disclosure Suit
A five-year-old stockholder complaint triggered by a biopharmaceutical company's misleading disclosures about a cancer drug's progress ended Wednesday with Delaware Chancery Court approval of corporate governance reforms and a $2.33 million...To view the full article, register now.
Already a subscriber? Click here to view full article